Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158425 | 0.89 | ACLY (0.54) | ACLYSLC10A6EDNRAKDM4EMEN1 | |
| SCHEMBL7537977 | 0.81 | ACLY (0.52) | ACLYMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL2248038 | 0.79 | ALDH1A1 (0.61) | ACLYKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL7537970 | 0.79 | ACLY (0.50) | ACLYKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL7531342 | 0.78 | ACLY (0.54) | ACLYSLC10A6KDM4EMEN1KMT2A | |
| SCHEMBL6611218 | 0.78 | SLC40A1 (0.47) | ACLYSLC10A6EDNRAKDM4EMEN1 | |
| SCHEMBL2747643 | 0.77 | ACLY (0.53) | ACLYEDNRAKDM4EMEN1KMT2A | |
| SCHEMBL11246570 | 0.77 | ALDH1A1 (0.68) | KDM4EMEN1KMT2ACYP3A4HSD17B10 | |
| SCHEMBL2747710 | 0.77 | ACLY (0.59) | ACLYKDM4ETSHR | |
| SCHEMBL2748302 | 0.76 | ACLY (0.55) | ACLYEDNRAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | ACLY 3169/4885SLC10A6 1440/4885EDNRA 18/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | ACLY 3169/4885SLC10A6 1440/4885EDNRA 18/4885 |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | ACLY 3169/4885SLC10A6 1440/4885EDNRA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.